Table 1. Patient characteristics of 8... | American Society of Hematology

Table 1.

Patient characteristics of 8 “heterogenous” individuals used in this study with AIDS-related Kaposi sarcoma (KS)

Patient	Sites of KS	CD4 count cells/mm³	CD8 count cells/mm³	HIV-1 viral load copies/mL	Therapy	ACTG staging
1	Pulmonary	160	754	< 50	HAART, paclitaxel	T1 l0
2	Cutaneous	229	622	13 291	HAART	T0 l1
3	Pulmonary	48	330	128 471	Paclitaxel	T1 l0
4	Visceral and pulmonary	111	289	59 225	Liposomal daunorubicin	T1 l0
5	Oral	354	754	< 50	HAART, paclitaxel	T1 l1
6	Cutaneous	50	99	510	HAART	T0 l1
7	Cutaneous	505	358	< 50	HAART	T0 l0
8	Cutaneous	497	627	> 500 000	None	T0 l1

Patient	Sites of KS	CD4 count cells/mm³	CD8 count cells/mm³	HIV-1 viral load copies/mL	Therapy	ACTG staging
1	Pulmonary	160	754	< 50	HAART, paclitaxel	T1 l0
2	Cutaneous	229	622	13 291	HAART	T0 l1
3	Pulmonary	48	330	128 471	Paclitaxel	T1 l0
4	Visceral and pulmonary	111	289	59 225	Liposomal daunorubicin	T1 l0
5	Oral	354	754	< 50	HAART, paclitaxel	T1 l1
6	Cutaneous	50	99	510	HAART	T0 l1
7	Cutaneous	505	358	< 50	HAART	T0 l0
8	Cutaneous	497	627	> 500 000	None	T0 l1

ACTG is the AIDS Clinical Trials Group Oncology Committee,²³ where (briefly) tumor status (T; 0 indicates cutaneous only; 1, more than cutaneous disease) and immunologic status (l; 0 indicates CD4 count < 150 cells/mm³; 1, CD4 count > 150 cells/mm³) are used to stage KS.

HAART indicates highly active antiretroviral therapy.

View Large

This Feature Is Available To Subscribers Only